>> How could they parity price when GILD has a 8-week option?
Exactly. I guess some analysts don't think, just put out vague statement like this, hope no one figures it out. I guess they could say it is parity if ABBV prices its 12-week regimen right at the middle of GILD's 8- and 12-week regimen. In reality that would be a premium over GILD's regimen as overall treatment naive market will be greater than experienced.
Market Data 
Markets 
AI
